For the first nine months of the COVID-19 pandemic, there were no officially approved outpatient treatments for combating the disease. From March 2020, when the virus first emerged in the United States, until that November, when the Food and Drug Administration authorized emergency use of monoclonal antibodies, health authorities advised that the infected do little but quarantine themselves, drink plenty of fluids and rest unless hospitalization was necessary.
During those chaotic final months of Donald Trump’s presidency, the medical establishment expressed extreme caution regarding outpatient treatments for the virus, and these warnings were amplified by major media hostile to the president, for example when he touted the anti-malaria medicine hydroxychloroquine.
Although an estimated 12% to 38% of prescriptions are written for FDA-approved drugs used “off-label” (including Botox and Viagra), Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, declared early on that providers should dispense only medicines proven to be safe and effective for COVID patients through “randomized, placebo-controlled trials.” These can take months or years to conduct, and often at great cost.
Vanderbilt University Medical Center is studying the effects of three “repurposed” drugs in treating mild and moderate symptoms of COVID-19.
The study, in partnership with the Duke University Clinical Research Institute, will examine the effectiveness of Ivermectin, Fluvoxamine, or Fluticasone on the symptoms of the illness.
Patients who survived COVID-19 have such strong natural immunity that their chance of reinfection or serious side effects is minimal, according to a new study published in The New England Journal of Medicine.
The study conducted by researchers in Qatar reviewed global databases for 353,000 coronavirus patients who were infected between Feb. 28, 2020 and April 28, 2021.
The researchers excluded about 87,500 people who were vaccinated, and found of the remaining population only 1,304 got reinfected, with none requiring ICU hospitalization.
A top Chinese health official said Wednesday that the government will begin counting coronavirus patients without symptoms in its official tally of cases of the virus, in what is a tacit acknowledgement that Beijing has underreported data on the pandemic.
China’s National Health Commission disclosed that the government is monitoring 1,541 people who have tested positive for coronavirus but have no symptoms.
Chang Jile, the head of the health agency, said at a press conference in Wuhan that the government will start reporting asymptomatic patient numbers Wednesday.
Fever, cough and shortness of breath are symptoms to watch for with the coronavirus, the CDC says.